Pyrrolobenzodiazepine-antibody conjugates
US10780096B2 · kind B2 · utility
4Cited by
72References
35Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 25, 2015 |
| Grant date | Sep 22, 2020 |
| Priority date | — |
| Expiry date | Jul 18, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.